Abstract
Lung cancer is considered the leading cause of cancer death in the word. Among all lung cancer cases, non-small cell lung cancer (NSCLC) accounts for 85%. Currently, chemotherapy is still the major therapeutic method of lung cancer. However, chemoresistance is a serious obstacle in treating NSCLC. Up to now, many reports have suggested that microRNAs(miRNAs) could contribute to lung cancer cell chemosensitivity. MicroRNAs, a class of endogenous non-coding small RNAs, regulate gene expression by binding to their complementary target messenger RNAs, leading to mRNA degradation or translational suppression. Numerous studies indicate that changes of specific miRNA expression may contribute to chemoresistance or chemosensitivity. Consequently, targeting specific miRNAs could become an effective approach to predict the therapeutic effect of different anticancer agents, achieve more effective personalised treatments and enhance chemosensitivity. This review summarizes the several major drug resistance mechanisms and focuses on the roles of miRNAs in regulating chemoresistance in NSCLC.
Keywords: MicroRNAs, chemotherapy, drug resistance, cisplatin, non-small cell lung cancer (NSCLC), chemosensitivity.
Current Pharmaceutical Design
Title:The Roles of microRNAs in Regulating Chemotherapy Resistance of Non-Small Cell Lung Cancer
Volume: 23 Issue: 39
Author(s): Xiaoxuan Wei, Xiaoyan Shen, Yanchen Ren and Weidong Hu*
Affiliation:
- Department of Thoracic Oncology, Wuhan University, Zhongnan Hospital of Wuhan University, Wuhan, 430071,China
Keywords: MicroRNAs, chemotherapy, drug resistance, cisplatin, non-small cell lung cancer (NSCLC), chemosensitivity.
Abstract: Lung cancer is considered the leading cause of cancer death in the word. Among all lung cancer cases, non-small cell lung cancer (NSCLC) accounts for 85%. Currently, chemotherapy is still the major therapeutic method of lung cancer. However, chemoresistance is a serious obstacle in treating NSCLC. Up to now, many reports have suggested that microRNAs(miRNAs) could contribute to lung cancer cell chemosensitivity. MicroRNAs, a class of endogenous non-coding small RNAs, regulate gene expression by binding to their complementary target messenger RNAs, leading to mRNA degradation or translational suppression. Numerous studies indicate that changes of specific miRNA expression may contribute to chemoresistance or chemosensitivity. Consequently, targeting specific miRNAs could become an effective approach to predict the therapeutic effect of different anticancer agents, achieve more effective personalised treatments and enhance chemosensitivity. This review summarizes the several major drug resistance mechanisms and focuses on the roles of miRNAs in regulating chemoresistance in NSCLC.
Export Options
About this article
Cite this article as:
Wei Xiaoxuan , Shen Xiaoyan , Ren Yanchen and Hu Weidong *, The Roles of microRNAs in Regulating Chemotherapy Resistance of Non-Small Cell Lung Cancer, Current Pharmaceutical Design 2017; 23 (39) . https://dx.doi.org/10.2174/1381612823666171018105207
DOI https://dx.doi.org/10.2174/1381612823666171018105207 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Hypothesis for the Relationship between Depression and Cancer: Role of Ca2+/cAMP Signalling
Anti-Cancer Agents in Medicinal Chemistry Atrial Fibrillation Recurrence: The Roles of Hypertension, Duration of Atrial Fibrillation Disease, and Prolonged Signal-Averaged P Wave Duration
Current Cardiology Reviews QSAR and 3D-QSAR Models in the Field of Tubulin Inhibitors as Anticancer Agents
Current Topics in Medicinal Chemistry Development of Arene Ruthenium Antitumor Complexes
Mini-Reviews in Medicinal Chemistry Integrins as Novel Drug Targets for Overcoming Innate Drug Resistance
Current Cancer Drug Targets Protein Microarrays: Technological Aspects, Applications and Intellectual Property
Recent Patents on Biotechnology Targeting EGFR in Pancreatic Cancer Treatment
Current Drug Targets Natural Products from Cyanobacteria with Antimicrobial and Antitumor Activity
Current Pharmaceutical Biotechnology Oxidative Stress Upregulates PDCD4 Expression in Patients with Gastric Cancer via miR-21
Current Pharmaceutical Design Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers
Current Drug Targets The Metabolism of Anticancer Drugs by the Liver: Current Approaches to the Drug Development Process
Current Drug Metabolism Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia
Current Medicinal Chemistry Lung Cancer- Current Clinical Profile and Diagnostic Challenges
Current Respiratory Medicine Reviews Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy
Current Radiopharmaceuticals Thin Metal Films in Resistivity-based Chemical Sensing
Current Analytical Chemistry Antibody-Targeted Immunoliposomes for Cancer Treatment
Mini-Reviews in Medicinal Chemistry Differential Serum Level of Specific Haptoglobin Isoforms in Small Cell Lung Cancer
Current Proteomics N-Heterocyclic Dronic Acids: Applications and Synthesis
Mini-Reviews in Medicinal Chemistry The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations
Current Cancer Drug Targets Poly(Ethylene Glycol) Amphiphilic Copolymer for Anticancer Drugs Delivery
Anti-Cancer Agents in Medicinal Chemistry